Your browser is no longer supported. Please, upgrade your browser.
ESPR Esperion Therapeutics, Inc. daily Stock Chart
ESPR [NASD]
Esperion Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.33 Insider Own0.10% Shs Outstand22.31M Perf Week-0.70%
Market Cap826.59M Forward P/E- EPS next Y-4.98 Insider Trans-97.39% Shs Float19.57M Perf Month-4.85%
Income-75.00M PEG- EPS next Q-1.44 Inst Own90.00% Short Float24.36% Perf Quarter230.51%
Sales- P/S- EPS this Y-47.10% Inst Trans6.36% Short Ratio2.16 Perf Half Y200.00%
Book/sh10.14 P/B3.65 EPS next Y18.40% ROA-28.00% Target Price47.33 Perf Year103.13%
Cash/sh9.48 P/C3.91 EPS next 5Y-5.70% ROE-29.20% 52W Range9.40 - 48.21 Perf YTD195.93%
Dividend- P/FCF- EPS past 5Y38.00% ROI- 52W High-23.15% Beta2.75
Dividend %- Quick Ratio13.70 Sales past 5Y- Gross Margin- 52W Low294.15% ATR2.91
Employees44 Current Ratio13.70 Sales Q/Q- Oper. Margin- RSI (14)55.58 Volatility4.67% 5.66%
OptionableYes Debt/Eq0.01 EPS Q/Q-120.30% Profit Margin- Rel Volume0.39 Prev Close37.54
ShortableYes LT Debt/Eq0.00 EarningsMay 24 AMC Payout- Avg Volume2.21M Price37.05
Recom2.20 SMA200.50% SMA5014.88% SMA200117.16% Volume847,800 Change-1.31%
Mar-30-17Upgrade UBS Neutral → Buy $23 → $52
Mar-20-17Upgrade Credit Suisse Underperform → Neutral
Feb-28-17Upgrade Citigroup Neutral → Buy
Feb-23-17Reiterated RBC Capital Mkts Sector Perform $20 → $30
Nov-14-16Downgrade Citigroup Buy → Neutral
Jul-05-16Downgrade WallachBeth Buy → Hold $35
Jun-30-16Reiterated Needham Buy $77 → $25
Jun-29-16Downgrade RBC Capital Mkts Outperform → Sector Perform $30 → $15
Jun-29-16Downgrade JP Morgan Overweight → Neutral
Jun-29-16Downgrade Credit Suisse Neutral → Underperform
Feb-26-16Reiterated Chardan Capital Markets Neutral $18 → $13
Feb-25-16Reiterated Stifel Buy $105 → $64
Dec-15-15Reiterated RBC Capital Mkts Outperform $65 → $40
Nov-06-15Reiterated RBC Capital Mkts Outperform $105 → $65
Oct-26-15Initiated WallachBeth Buy $34
Oct-26-15Initiated Lake Street Buy $94
Sep-30-15Upgrade Chardan Capital Markets Sell → Neutral $29 → $18
Sep-29-15Reiterated Chardan Capital Markets Sell $36 → $29
Aug-31-15Reiterated Chardan Capital Markets Sell $40 → $36
Aug-19-15Downgrade Needham Strong Buy → Buy $130 → $115
Apr-11-17 07:02AM  3 Clinical-Stage Biotech Stocks That Could Be About to Strike It Rich Motley Fool
Apr-10-17 06:51PM  Cramer's lightning round: I may be alone on this, but this e-commerce play is going higher CNBC +7.57%
Apr-07-17 09:30AM  The Zacks Analyst Blog Highlights: Esperion Therapeutics, Vertex Pharmaceuticals, Nektar Therapeutics, Argos Therapeutics and Cidara Therapeutics Zacks
Apr-06-17 09:32AM  3 of the Best & Worst Performing Drug Stocks of Q1 Zacks
Mar-31-17 08:21AM  Could Pfizer Buy Esperion Therapeutics? Motley Fool
Mar-30-17 04:20PM  The 3 Best Cholesterol Drug Stocks to Buy in 2017 Motley Fool
04:08PM  Which Biotechs Are Buyable As Sector Recovers In 2017? Investor's Business Daily
10:33AM  5 Top Performing Stocks of the Best ETF of Q1 Zacks
09:03AM  Esperion Therapeutics upgraded by UBS
Mar-28-17 04:30PM  Esperion to Participate in Fireside Chat at the 16th Annual Needham Healthcare Conference GlobeNewswire -6.82%
Mar-24-17 12:00PM  3 Hot Biotech Stocks Now Motley Fool
Mar-21-17 10:10AM  Company News for March 21, 2017 Zacks -5.26%
09:32AM  Biotech Premarket Movers: Esperion, Minerva and BioCryst
09:30AM  The Difference Between Spectacular News and No News Accesswire
Mar-20-17 08:08PM  Esperion Therapeutics Inc (ESPR): Get It While Its Cheap Insider Monkey +74.14%
06:21PM  After-hours buzz: ESPR, NKTR, MMSI & more at CNBC
05:02PM  Here's What Pushed Esperion Therapeutics Inc Stock Higher Today at Motley Fool
04:09PM  Esperion And Medicines Co. Recover From Amgen-Induced Pitfall
02:03PM  How to Trade Monday's Most Active Stocks - AMD, Esperion Therapeutics, Nokia and More
12:42PM  Nektar, AMD, Esperion, and More: Heres Why These Five Stocks Are Surging at Insider Monkey
12:05PM  Esperion Gets FDA Nod for Cholesterol Drug Program at Investopedia
11:01AM  Esperion Therapeutics stock surges 52% after it says the FDA gave its drug program positive feedback at MarketWatch
10:55AM  Mondays Top Biopharma Movers
09:35AM  Biotech Premarket Movers: CytomX, Aevi, Esperion
07:46AM  ESPERION THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:32AM  Esperion Therapeutics Sees Clear FDA Path For Its Heart Drug at Forbes
07:30AM  Esperion Announces FDA Confirmation Regarding Regulatory Pathway to Approval for an LDL-C Lowering Indication for Bempedoic Acid GlobeNewswire
Mar-17-17 04:50PM  Esperion's Dive On Amgen Heart Study 'Counterintuitive' On Pricing -20.17%
04:28PM  Amgen Tanks On Heart Study; Shares Of Other Drugmakers Tumble
02:56PM  Amgen, Esperion, AmTrust Financial and More: What is Going On With These Falling Stocks? at Insider Monkey
01:18PM  Here's Why Amgen, The Medicines Company, and Esperion Therapeutics Are All Tanking Today at Motley Fool
11:03AM  [video]AveXis, Esperion and Amgen Among Biotech Movers
Mar-14-17 04:06PM  Amgen Could Boost Rivals On Positive Heart-Disease Study: Analyst
Mar-09-17 08:15AM  Esperion Therapeutics (ESPR) Jumps: Stock Moves Up 8.6%
Mar-08-17 04:26PM  Puma Leads Massive Biotech Surge As Esperion Hits 15-Month High +8.59%
Mar-07-17 08:47AM  ESPERION THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:30AM  Esperion Announces Initiation of Phase 2 Triplet Oral Therapy Study of Bempedoic Acid/Ezetimibe/Atorvastatin GlobeNewswire
Mar-06-17 08:30AM  Esperion Announces Oral Presentation on Genetic Validation of ATP Citrate Lyase Inhibition at the American College of Cardiology 66th Annual Scientific Session GlobeNewswire
Mar-02-17 03:34PM  Biotechs Breaking Out On Drug Development News at Forbes
Mar-01-17 04:21PM  Here's Why Esperion Therapeutics Inc Stock Popped Today at Motley Fool +16.32%
Feb-28-17 01:04PM  ESPERION THERAPEUTICS, INC. Financials
Feb-27-17 07:39PM  Cramer's lightning round: The only Chinese stock I will recommend at CNBC +6.50%
Feb-24-17 05:42PM  3 Biotech Long Shots: Boom Or Bust? at Motley Fool
Feb-22-17 08:04AM  Esperion Therapeutics reports 4Q loss -7.74%
07:47AM  ESPERION THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
07:30AM  Esperion Provides Bempedoic Acid Development Program Update; Reports Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
Feb-15-17 04:30PM  Esperion to Participate in Fireside Chat at RBC Capital Markets Global Healthcare Conference GlobeNewswire
Feb-13-17 04:07PM  Esperion Positioned to Capitalize on Phase III Trials
Feb-09-17 12:37PM  Harry Boxers stocks to watch: biotechnology and technology at MarketWatch
Feb-08-17 01:49PM  Four Biotech Stocks Breaking Out at Forbes
Feb-07-17 12:50PM  Whats Next For Esperion Therapeutics Inc (ESPR)? at Insider Monkey +14.04%
Feb-06-17 09:30AM  Mergers & Acquisitions Could be a Key Catalyst Sending These Biotech Stocks to New Highs in 2017 Accesswire +7.42%
Feb-03-17 03:38PM  Why Esperion Therapeutics, Inc. Is Soaring Today at Motley Fool +29.25%
Jan-25-17 08:05AM  Esperion Completes Enrollment of Pivotal Phase 3 Long-Term Safety and Tolerability Study of Bempedoic Acid in Patients with Hypercholesterolemia GlobeNewswire +5.89%
Jan-09-17 04:07PM  ESPERION THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:05AM  Esperion Announces Initiation of Global Cardiovascular Outcomes Trial for Bempedoic Acid GlobeNewswire
Jan-08-17 04:00PM  Esperion Announces Initiation of Three Pivotal Phase 3 Studies for Bempedoic Acid GlobeNewswire
Jan-04-17 05:00PM  Esperion to Present at the 35th Annual J.P. Morgan Healthcare Conference GlobeNewswire +7.84%
Dec-09-16 05:26PM  Esperion Therapeutics Inc (ESPR): Smart Money Doubles Down at Insider Monkey
04:31PM  ESPERION THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E
Dec-02-16 04:05PM  Amgen, Regeneron 2017 LDL-Busters Could Boost This Small-Cap Biotech
Nov-29-16 11:59AM  Esperion Therapeutics, Inc. :ESPR-US: Earnings Analysis: Q3, 2016 By the Numbers : November 29, 2016
Nov-28-16 04:30PM  Esperion Therapeutics Announces Publication of Definitive Paper on Bempedoic Acid Mechanism of Action in Nature Communications GlobeNewswire -6.46%
Nov-09-16 04:30PM  Esperion Therapeutics to Present at the Stifel 2016 Healthcare Conference GlobeNewswire +9.52%
Nov-03-16 07:11PM  Esperion Therapeutics reports 3Q loss -7.57%
04:39PM  ESPERION THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
04:37PM  ESPERION THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
04:05PM  Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports Third Quarter 2016 Financial Results GlobeNewswire
Nov-01-16 04:30PM  Esperion Therapeutics to Present at the Credit Suisse 25th Annual Healthcare Conference GlobeNewswire
12:39PM  Pfizer's Surprising News Upends the Market for Next-Gen Cholesterol Busters at Motley Fool
Oct-14-16 09:22AM  Credit Suisse Changes Its View On Esperion Therapeutics, Raises Price Target -7.38%
Oct-13-16 07:46AM  ESPERION THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits +5.60%
07:30AM  Bempedoic Acid Global Phase 3 Clinical Program to Include Patients on Any Statin at Any Dose GlobeNewswire
Sep-23-16 07:58AM  7 Unusual-Volume Stocks That Are About to Break Out
Sep-21-16 08:25AM  Esperion Therapeutics (ESPR) in Focus: Stock Jumps 18.1%
Sep-14-16 01:44PM  Esperion Therapeutics, Inc. :ESPR-US: Earnings Analysis: Q2, 2016 By the Numbers : September 14, 2016
Aug-26-16 08:36AM  Is Esperion Therapeutics (ESPR) Stock a Solid Choice Right Now?
Aug-09-16 11:05AM  3 Biotech Stocks With Catalysts That Have 90% to 500% Upside Potential at 24/7 Wall St.
Aug-04-16 07:51PM  Esperion Therapeutics reports 2Q loss
04:32PM  ESPERION THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
04:05PM  Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports Second Quarter 2016 Financial Results GlobeNewswire
Jul-15-16 02:44PM  It's Time to Bring the Heat +7.52%
Jul-08-16 12:06PM  These 5 Stocks Are Breaking Out +6.17%
10:40AM  Beleaguered Esperion Therapeutics Inc. (ESPR) and Two Other Struggling Companies Register Insider Buying at Insider Monkey
Jul-05-16 09:01AM  Morning Movers: Tesla Tanks on Delivery Miss; Rowan Sinks at Barrons.com
Jul-02-16 12:01AM  [$$] Charting the Market at Barrons.com
Jun-29-16 05:47PM  Why AeroVironment, Southwestern Energy, and Esperion Therapeutics Slumped Today at Motley Fool -40.30%
04:04PM  Fitbit, Lipocine Top Wednesdays 52-Week Low Club at 24/7 Wall St.
01:15PM  Esperion Therapeutics Inc Sinks After FDA Says, "Ask Us in 2019" at Motley Fool
11:42AM  Can Esperion Therapeutics Ever Regain Wall Street's Trust? at Forbes
11:09AM  Esperion (ESPR) Offers Updates on LDL-Lowering Candidate
08:26AM  Morning Movers: Transocean Jumps on Upgrade; Esperion Tumbles at Barrons.com
Jun-28-16 04:43PM  Esperion Falls on Regulatory Setback for Cholesterol-Lowering Pill +8.30%
04:22PM  ESPERION THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:06PM  Esperion Slumps on Lack of FDA Clarity for Cholesterol Drug at Bloomberg
04:05PM  Esperion Therapeutics Provides Clinical Development and Regulatory Update for Bempedoic Acid GlobeNewswire
Jun-15-16 04:07PM  ESPERION THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders +8.43%
Jun-02-16 01:00PM  Esperion Therapeutics, Inc. :ESPR-US: Earnings Analysis: Q1, 2016 By the Numbers : June 2, 2016
Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Its lead product candidate is Bempedoic acid, an inhibitor of ATP-citrate lyase that reduces cholesterol biosynthesis that is in Phase III long-term safety and tolerability study. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
OMENN GILBERT SDirectorMar 21Buy42.261,00042,2601,000Mar 22 08:02 AM
JANNEY DANIELDirectorMar 21Sale45.80350,00016,029,2631,359,967Mar 23 04:45 PM
GOLDSTEIN DOV A MDDirectorMar 21Sale43.48487,35821,190,3261,149,767Mar 23 04:37 PM
Lalwani Narendra D.Chief Operating OfficerNov 01Buy9.935,00049,6505,000Nov 03 05:58 PM
MCGOVERN MARK EDirectorJul 06Buy10.004,40044,0005,000Jul 07 07:17 AM
MCGOVERN MARK EDirectorJul 05Buy10.006006,000600Jul 07 07:17 AM
MAYLEBEN TIMOTHY MPresident & CEOMay 04Buy14.857,000103,95041,614May 05 07:33 AM